BHC Bausch Health Companies Inc.

26.68
-0.33  -1%
Previous Close 27.01
Open 26.94
52 Week Low 11.15
52 Week High 30.38
Market Cap $9,475,428,733
Shares 355,158,914
Float 311,917,499
Enterprise Value $32,894,800,274
Volume 2,643,293
Av. Daily Volume 3,558,456
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
XIPERE (Suprachoroidal CLS-TA)
Macular edema associated with non-infectious uveitis
NDA Filing
NDA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IDP-120
Acne
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
NOV03 (perfluorohexyloctane) - (Gobi Study)
Dry Eye Disease Associated With Meibomian Gland Dysfunction
Phase 3
Phase 3
Phase 3 completion of enrollment announced January 19, 2021.
IDP-126
Acne
Phase 3
Phase 3
Phase 3 trial ongoing.
NOV03 (perfluorohexyloctane) - (Mojave Study)
Dry Eye Disease Associated With Meibomian Gland Dysfunction
Phase 3
Phase 3
Phase 3 trial initiation announced November 24, 2020.
Amiselimod S1P6 Modulator
Phase 2
Phase 2
Phase 2 trial to commence 1H 2021.
IDP-124
Atopic Dermatitis
Phase 3
Phase 3
Phase 3 trials completed. One of two trials met primary endpoint.
Rifaximin
Small intestinal bacterial overgrowth (SIBO)
Phase 2
Phase 2
Phase 2 trial planned.
Rifaximin
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial to commence 3Q 2021.
EM-100
Allergic conjunctivitis
Approved
Approved
FDA approval announced September 25, 2020.
Rifaximin
Overt hepatic encephalopathy
Phase 2
Phase 2
Phase 2 data met primary endpoint - March 31, 2020.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
Approved
Approved
FDA approval announced April 25, 2019.
IDP-123
Acne
Approved
Approved
FDA Approval announced December 19, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approved
Approved
FDA approval announced February 25, 2019.
IDP-122
Psoriasis
Approved
Approved
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-121
Acne
Approved
Approved
FDA Approval announced August 24, 2018.
ULTRA - 7 days
Contact lens
Approved
Approved
Approval announced March 2, 2018.
Plenvu (NER1006)
Bowel cleansing
Approved
Approved
Approval announced May 7, 2018.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Approved
Approved
Approval announced November 2, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
Approved
Approved
Approval announced December 22, 2017.
Brodalumab
Psoriasis
Approved
Approved
Approved February 15, 2017.

Latest News

  1. LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that LUMIFY® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea.

    "The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch + Lomb/International. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in South Korea in the second half of 2021."

    Since its initial U.S. approval…

    LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that LUMIFY® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea.

    "The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch + Lomb/International. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in South Korea in the second half of 2021."

    Since its initial U.S. approval in 2017, LUMIFY has achieved the No. 1 dollar share among redness relievers (at 40% share in the latest 52 weeks)1, became the No. 1 eye doctor recommended brand within the first few months of launch,2 and brought in more than a million first-time users into the eye redness reliever category3 in the United States.

    Additional regulatory submissions for LUMIFY are underway in multiple countries.

    About LUMIFY Redness Reliever Eye Drops

    In the United States and Korea, LUMIFY is the first and only over-the-counter eye drop developed with low dose brimonidine tartrate 0.025% for the relief of redness of the eye due to minor eye irritations. Unlike other redness relievers, LUMIFY selectively targets redness, with a reduced risk of certain side effects, including rebound redness and loss of efficacy over time, when used as directed. For more information on LUMIFY, U.S. residents can visit www.lumifydrops.com.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    1. Consumer Data Science: Total US Omnichannel Data Ending 12-27-20.
    2. Consumer Data Science: IQVIA ProVoice Data Ending Q4 2020.
    3. Consumer Data Science: IRI, Total US All Outlet Panel Data Ending 12-27-20.

    LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates. Any other product/brand names are trademarks of the respective owners. © 2021 Bausch & Lomb Incorporated or its affiliates.

    Investor Contact:

    Media Contact:

    Arthur Shannon

    Lainie Keller

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free)



     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    (PRNewsfoto/Bausch Health Companies)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/south-koreas-mfds-approves-lumify-eye-drops-301212137.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  2. Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens Scleral Lenses on Patients

    LAVAL, QC, Jan. 20, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that two poster presentations will feature data on the new Bausch + Lomb INFUSE silicone hydrogel (SiHy) daily disposable contact lenses during the virtual Global Specialty Lens Symposium (GSLS) Annual Meeting, which takes place Jan. 21-23, 2021. Bausch + Lomb also will offer attendees the opportunity to participate in a presentation about its Zenlens scleral lenses.

    "The continued response from patients has been overwhelmingly positive…

    Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens Scleral Lenses on Patients

    LAVAL, QC, Jan. 20, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that two poster presentations will feature data on the new Bausch + Lomb INFUSE silicone hydrogel (SiHy) daily disposable contact lenses during the virtual Global Specialty Lens Symposium (GSLS) Annual Meeting, which takes place Jan. 21-23, 2021. Bausch + Lomb also will offer attendees the opportunity to participate in a presentation about its Zenlens scleral lenses.

    "The continued response from patients has been overwhelmingly positive since we launched this breakthrough new lens last year in the United States, Canada and other countries around the world.* In fact, in a survey among patients who tried Bausch + Lomb INFUSE lenses, 97% of patients agreed Bausch + Lomb INFUSE lenses provide crisp, clear vision throughout the day, and 94% of patients agreed Bausch + Lomb INFUSE helps keep contact lenses from feeling dry,"1 said Joseph C. Papa, chairman and CEO, Bausch Health. "We are proud to continue to support ongoing research on this unique lens to help eye care professionals understand its clinical benefits and relevance for patients."

    Bausch + Lomb INFUSE Poster Presentations

    The Bausch + Lomb INFUSE poster presentations will be accessible to conference attendees via the GSLS website from Jan. 21-23, 2021.

    The poster presentations are as follows:

    • Scheuer, Catherine et al. "Impact of a Novel Contact Lens on Maintaining the Native State of a Tear Film Protein"
      • An in vitro study to investigate the ability of a contact lens solution to stabilize the representative tear film protein lysozyme in its native state.
    • Steffen, Robert et al. "Evaluation of the Stability of Surface Water Characteristics of Contact Lenses Using Refractive Index Shifts after Wear of Daily Disposable Lenses"
      • A study to investigate surface water stability using refractive index shifts after insertion for four unique polymers, kalifilcon A, delefilcon A, verofilcon A and nesofilcon A.

    Zenlens™ Event Presentation

    On Jan. 22, 2021, from 5:15 to 5:45 p.m. ET, Bausch + Lomb will host a presentation featuring one of its prominent custom contact lenses, Zenlens scleral lenses, led by Jason Jedlicka O.D., FAAO, FSLS, FCLSA, associate professor and director of the Cornea and Contact Lens Service, Indiana University School of Optometry. During the event, "Using Technology for Fitting Success", Dr. Jedlicka will discuss how technology can help create fitting efficiencies using the Zenlens lenses through the use of corneal topography, scleral topography and anterior segment optical coherence tomography.

    About Bausch + Lomb INFUSE Contact Lenses

    Bausch + Lomb INFUSE contact lenses are the only SiHy daily disposable with a next generation material infused with ProBalance Technology that work together to help maintain ocular surface homeostasis to help minimize symptoms of contact lens dryness and discomfort for exceptional clarity and comfort. The ProBalance Technology™ formula is infused into the lens material during the manufacturing process. These proprietary ingredients are released during lens wear. Bausch + Lomb INFUSE combines exceptional breathability for healthy lens wear with high moisture content and a low modulus. It also maintains 96% of its moisture for a full 16 hours. For more information on Bausch + Lomb INFUSE contact lenses, visit http://www.bauschinfuse.com/.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    * Bausch + Lomb INFUSE silicone hydrogel daily disposable contact lenses are branded as BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses in Canada.

    References

    1. Results of an online survey with patients who completed an evaluation program for Bausch + Lomb INFUSE contact lenses and wore their trial lenses for ≥7 days (n=777). Survey results include patients who strongly agreed, agreed, or slightly agreed (on a 6-point agreement scale) with the surveyed statement, with a margin of error ±1.7%.

    ®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.

    Any other product/brand names are trademarks of the respective owners.

    © 2021 Bausch & Lomb Incorporated or its affiliates.

    MTB.0030.USA.21

    Investor Contact:

    Media Contact:

    Arthur Shannon 

    Lainie Keller

                                              

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free)                                                  



     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    (PRNewsfoto/Bausch Health Companies)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-announces-scientific-data-on-bausch--lomb-infuse-silicone-hydrogel-daily-disposable-contact-lenses-to-be-presented-at-the-virtual-global-specialty-lens-symposium-301211447.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  3. Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian Gland Dysfunction

    LAVAL, QC and HEIDELBERG, Germany, Jan. 19, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the first of two Phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry eye disease (DED) associated with Meibomian gland dysfunction…

    Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian Gland Dysfunction

    LAVAL, QC and HEIDELBERG, Germany, Jan. 19, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the first of two Phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled with a total of 599 participants.

    Additionally, a Phase 2 clinical study (SEECASE) evaluating the efficacy, safety, and tolerability of NOV03 (perfluorohexyloctane) ophthalmic solution in patients with DED associated with MGD has been published in Cornea: The Journal of Cornea and External Disease. In the study, NOV03 met its primary efficacy endpoint of statistically significant improvement of total corneal fluorescein staining over control at eight weeks. NOV03 also showed statistically significant improvement of certain symptoms, such as severity and frequency of dryness and burning/stinging of the eyes, over the entire duration of the Phase 2 study.1

    "We are committed to addressing the unmet needs of patients, and believe NOV03, if approved, may be  a first-in-class treatment option for the millions of patients who suffer from Dry eye disease associated with Meibomian gland dysfunction," said Joseph C. Papa, chairman and CEO, Bausch Health. "This continued progress in our Phase 3 program and the published results of the SEECASE study are both exciting milestones in our development journey for NOV03." 

    "Dry eye disease is one of the most common ocular surface disorders causing discomfort for millions of Americans," said Joseph Tauber, M.D., founder of Tauber Eye Center in Kansas City, Mo., and lead author of the publication. "Given the key role Meibomian gland dysfunction plays in the pathogenesis of this disease, we are very encouraged by the findings in the SEECASE study, which demonstrate the potential for NOV03 as a possible treatment for those with highly symptomatic DED associated with MGD, and look forward to the results of the Phase 3 studies."

    Summary of Phase 2 SEECASE Study Results

    The prospective, multicenter, randomized, double-masked, saline-controlled clinical study evaluated NOV03 at two dosing regimens. The data published was based on results from 336 patients age 18 years or older who were randomized to one of four treatment groups: NOV03 four times daily (QID), NOV03 twice daily (BID), saline BID or saline QID (a 2:2:1:1 ratio). The study met its primary efficacy endpoint of statistically significant improvement of total corneal fluorescein staining (tCFS) over control at eight weeks. Data showed a change from baseline of tCFS over control, for both dosing regimens (QID and BID, P < 0.001 and P = 0.009, respectively). Effects  on tCFS and symptoms started at two weeks after start of treatment and were maintained over the study duration. The effects were dosing schedule dependent. NOV03 was well tolerated with instillation site reactions below 3% in both treatment regimens.1

    The SEECASE study was conducted at 12 ophthalmology practices in the United States with patients who had a history of DED in both eyes and if one eye (the same eye) met the inclusion criteria at screening and at randomization time. Several symptom assessments such as Eye Dryness Score measured using visual analog scale (VAS), VAS for other symptoms such as burning/stinging, itching, blurred vision, and sensitivity to light, and Ocular Surface Disease Index (OSDI) were evaluated to assess the effect of NOV03 on DED symptomatology.1

    Patients treated with NOV03 also experienced statistically significant improvement of certain DED symptoms over the entire duration of the Phase 2 study. Changes from baseline were statistically significant compared with those of the control group at week eight [P < 0.001 (QID) and P = 0.002 (BID)]. Other symptoms evaluated included burning/stinging, sticky feeling, foreign body sensation, itching, blurred vision, sensitivity to light and pain. The following treatment emergent adverse events (TEAEs) reported by more than 2% of subjects were blurred vision in the NOV03 QID group, eye irritation in the NOV03 BID group and eye pain in the saline group. Overall the number of patients reporting at least one TEAE was similar between the treatment groups.1

    "The results demonstrated in the SEECASE study support NOV03 as a potential new treatment option for patients with DED associated with MGD, and we look forward to learning the results from both of the Phase 3 studies," said Christian Roesky, Ph.D., CEO, Novaliq GmbH.

    About NOV03 (perfluorohexyloctane) Ophthalmic Solution

    NOV03 is an investigational, proprietary, water-free and preservative-free solution, based on patented EyeSol® technology from Novaliq GmbH.2 In 2019, Bausch Health and Bausch + Lomb acquired an exclusive license for the commercialization and development of NOV03 in the United States and Canada, and together, they announced in November 2020 that they have initiated the second of two Phase 3 studies to evaluate NOV03.

    About Novaliq

    Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.  

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at http://www.bauschhealth.com/.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    References

    1. Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krösser S; SEECASE study group. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. Cornea. 2020 Dec 22; Publish Ahead of Print.

    2. In December 2019, Bausch Health acquired the rights from Novaliq GmbH to pursue development and commercialization of NOV03 for DED and combination products based on NOV03 in additional ophthalmic indications in the United States and Canada.

    Any product/brand names and/or logos are trademarks of the respective owners. © 2021 Bausch & Lomb Incorporated or its affiliates. NPR.0025.USA.21

    Novaliq Media Contact:

    Simone Angstmann-Mehr

      



     

     

     

    Bausch Health Investor Contact:

    Arthur Shannon

     

    (514) 865-3855

    (877) 281-6642 (toll free)



    Bausch Health Media Contact:

    Lainie Keller

     

    (908) 927-1198

     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane-301210541.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  4. LAVAL, QC, Jan. 12, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") will provide a preliminary update on its fourth-quarter and full-year 2020 financial results and the continued pace of its business recovery from the COVID-19 pandemic tomorrow, Jan. 13, 2021, during a fireside chat at 10 a.m. ET at the 39th Annual J.P. Morgan Healthcare Conference.

    Bausch Health expects its revenue in the fourth quarter of 2020 will be greater than $2.20 billion. For the full year of 2020, the Company anticipates it will outperform the high end of its latest revenue guidance range of $7.80 – $8.00 billion.1 

    "Bausch Health's preliminary fourth-quarter and full-year 2020 financial results demonstrate that our Company…

    LAVAL, QC, Jan. 12, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") will provide a preliminary update on its fourth-quarter and full-year 2020 financial results and the continued pace of its business recovery from the COVID-19 pandemic tomorrow, Jan. 13, 2021, during a fireside chat at 10 a.m. ET at the 39th Annual J.P. Morgan Healthcare Conference.

    Bausch Health expects its revenue in the fourth quarter of 2020 will be greater than $2.20 billion. For the full year of 2020, the Company anticipates it will outperform the high end of its latest revenue guidance range of $7.80 – $8.00 billion.1 

    "Bausch Health's preliminary fourth-quarter and full-year 2020 financial results demonstrate that our Company is continuing its business recovery from the effects of the COVID-19 pandemic driven by strong execution across our businesses. For the full year of 2020, we anticipate our revenue will outperform the high end of our latest revenue guidance range, and we also expect a strong finish to the year with regard to Adjusted EBITDA (non-GAAP)," said Joseph C. Papa, chairman and CEO, Bausch Health. "We look forward to releasing our full financial results for the fourth quarter and full year of 2020 next month."

    Additionally, due to strong cash flow in the fourth quarter of 2020, Bausch Health expects to exceed $1 billion in cash generated from operations for the full year of 2020. In total, the Company repaid approximately $900 million of debt in 2020 from cash generated from operations and more efficient cash management, and has no debt maturities or mandatory amortization payments until 2024.

    Bausch Health Will Publish Company Update Presentation on Jan. 13, 2021 at 7:00 a.m. ET

    Bausch Health will publish a brief company update presentation tomorrow, Jan. 13, 2021, at 7 a.m. ET, that is designed to complement the remarks provided by management at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will provide an overview of the Company's recent performance and offer insight into future catalysts for 2021 and beyond.

    The presentation will be available on the Investor Relations page of the Bausch Health Companies Inc. website at: https://ir.bauschhealth.com/events-and-presentations/2021. A live webcast and audio archive of the fireside chat will also be available on the Investor Relations page of the Company's website.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements related to the Company's preliminary update on fourth-quarter 2020 and full-year 2020 financial results (including anticipated range of revenue and expectations regarding adjusted EBITDA) and expected cash generated from operations. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's preliminary update on its 2020 financial results, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, assumptions regarding our 2020 full-year guidance with respect to expectations regarding base performance and management's belief regarding the impact of the COVID-19 pandemic and associated responses on such base performance and the operations and financial results of the Company generally, and the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    1 Based on guidance reaffirmed in November 2020.

    Investor Contact:

    Media Contact:

    Arthur Shannon

    Lainie Keller

     

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free) 



     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-provides-preliminary-update-on-fourth-quarter-and-full-year-2020-financial-results-and-business-recovery-301206826.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  5. LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET.

    A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch Health Companies Inc. website at: https://ir.bauschhealth.com/events-and-presentations/2021.

    About Bausch Health
    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily…

    LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET.

    A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch Health Companies Inc. website at: https://ir.bauschhealth.com/events-and-presentations/2021.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Investor Contact:                              

    Media Contact:

    Arthur Shannon                                    

    Lainie Keller

         

    (514) 856-3855                                      

    (908) 927-1198

    (877) 281-6642 (toll free) 



     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-to-participate-at-the-39th-annual-jp-morgan-healthcare-conference-301201474.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
View All Bausch Health Companies Inc. News